Terry Fox Cancer Research Laboratory, China Medical University Hospital, 2 Yuh-Der Road, Taichung, 404 Taiwan, Republic of China.
Pharmacogenomics. 2011 Apr;12(4):515-34. doi: 10.2217/pgs.10.209.
Over the past few decades, the incidence of cancer has rapidly increased all over the world and cancer remains a major threat to public health. It is believed that cancer results from a series of genetic alterations that lead to the progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predictor of drug and therapy responses or indeed as a target for novel gene therapy, is very promising. In this article, we have summarized the studies investigating the association between the XRCC5/XRCC6 dimer and the susceptibility to multiple cancers and discuss its role in carcinogenesis and its potential application to anticancer drug discovery.
在过去几十年中，癌症的发病率在全球范围内迅速增加，癌症仍然是公共卫生的主要威胁。人们认为癌症是由一系列遗传改变引起的，这些改变导致控制细胞增殖、分化、死亡和/或基因组稳定性的正常机制逐渐紊乱。因此，细胞对遗传损伤的反应及其通过多种 DNA 修复机制维持基因组稳定性的能力对于预防肿瘤的发生和进展至关重要。从同样的角度来看，DNA 修复作为预后生物标志物、药物和治疗反应预测因子，甚至作为新型基因治疗靶点的相对作用非常有前景。在本文中，我们总结了研究 XRCC5/XRCC6 二聚体与多种癌症易感性之间关系的研究，并讨论了其在致癌作用中的作用及其在抗癌药物发现中的潜在应用。
